LifeCycle for Prenatal Screening v4.0, v4.0 Rev 2 and v4.0 Rev 3. An in vitro diagnostic medical device (IVD) 의 리콜

Department of Health, Therapeutic Goods Administration에 따르면, 해당 리콜 는 Australia 에서 PerkinElmer 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    RC-2015-RN-00452-1
  • 사례 위험등급
    Class II
  • 사례 시작날짜
    2015-05-27
  • 사례 국가
  • 사례 출처
    DHTGA
  • 사례 출처 URL
  • 비고 / 경고
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • 데이터 추가 비고
  • 원인
    Wallac oy, a subsidiary of perkinelmer, has become aware that lifecycle for prenatal screening (5014-0020) may generate an incorrect risk calculation result for twins if lifecycle v4.0 risk calculation protocol is used and a particular sequence of actions occur.The issue is related to chorionicity correction of twins, which can be applied only with biomarker results for hcgb, papp-a and plgf in 1st trimester. if a second sample (e.G. 2nd trimester or dvpi examination) is attached to the same case, the moms should be cleared in order to recalculate the moms without chorionicity correction. if there are no gestational age calculation changes made, the 1st trimester sample moms will remain. since 1st trimester moms are chorionicity corrected when chorionicity is given, the mom values are too low resulting in unexpected risk values. if close to cut-off, a true risk value might end up on the opposite side of the cut-off and be reported as opposite risk result.
  • 조치
    Customers are advised that if they are using the affected software version and follow the sequence of actions that will result in the above issue, they should ensure that the MoM’s for hCGb, PAPP-A and PlGF biomarkers are always cleared before recalculating the risk when a second sample is added to the same case. This can be achieved by clearing the chorionicity information and saving the case data. PerkinElmer has developed a Database Investigation Script that can be used to determine if any affected calculations exists in customer’s LifeCycle database. Any decisions regarding the need to reassess/recalculate previously reported risk value results should be made on a case by case basis. Software v4.0 Rev 4 is under development and will correct this issue. Customers will be notified when the software update is available and it will be provided to them free of charge. This action has been closed-out on 11/08/2016.

Device

  • 모델명 / 제조번호(시리얼번호)
    LifeCycle for Prenatal Screening v4.0, v4.0 Rev 2 and v4.0 Rev 3. An in vitro diagnostic medical device (IVD)Catalogue number: 5014-0020ARTG Number: 216895
  • Manufacturer

Manufacturer